Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2009-014551-80Phase 2Completed
Phase 2, randomised, double-blind trial of BI-671800 in asthma (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: FEV1 % predicted trough change from baseline after 6 weeks. Started Jan 2010; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2009-014551-80.